{"id":15,"date":"2022-04-22T14:03:20","date_gmt":"2022-04-22T13:03:20","guid":{"rendered":"https:\/\/wilate.shinedezign.pro\/men\/?page_id=15"},"modified":"2025-10-24T08:35:38","modified_gmt":"2025-10-24T07:35:38","slug":"home","status":"publish","type":"page","link":"https:\/\/wilate.shinedezign.pro\/m-en\/","title":{"rendered":"Home"},"content":{"rendered":"\n\n\n
<\/div>\n\n\n\n
\n

wilate\u00ae<\/sup> is a high-purity plasma-derived von Willebrand factor and coagulation factor VIII (VWF\/FVIII) concentrate<\/h2>\n\n\n\n\n\n
\"\"<\/figure><\/div>\n\n\n\n\n\n

wilate\u00ae<\/sup><\/mark> was developed specifically for people with von Willebrand disease (VWD), and contains VWF and FVIII in a physiological 1:1 activity ratio, which may facilitate simple dosing and monitoring even when repeated dosing<\/a> is needed.4, 5<\/sup><\/p>\n\n\n\n

The purification process includes two virus inactivation steps in order to ensure a high-purity product free of viral contamination.4<\/sup><\/p>\n\n\n\n

Over 15 years of clinical and real-life experience have proven the efficacy and tolerability of wilate\u00ae<\/sup><\/mark> in people with all types of von Willebrand disease for surgery<\/a>, on-demand<\/a> treatment and prophylaxis<\/a>.1-3<\/sup><\/p>\n<\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n
\"\"<\/figure><\/div>\n\n\n\n

*Based on von Willebrand factor and factor VIII activity levels. FVIII, coagulation factor VIII; VWF, von Willebrand factor.<\/p>\n\n\n\n

<\/div>\n\n\n\n
\n
<\/div>\n\n\n\n

In the European Union, wilate\u00ae<\/sup> is indicated for the prevention and treatment of haemorrhage or surgical bleeding in von Willebrand disease, when desmopressin treatment alone is ineffective or contra-indicated6<\/sup><\/h3>\n\n\n\n
<\/div>\n<\/div><\/div>\n\n\n\n
<\/div>\n\n\n\n

Physiological 1:1 ratio of VWF and FVIII in wilate\u00ae<\/sup><\/h2>\n\n\n\n

One of the functions of VWF is to bind to and protect FVIII from proteolytic degradation.4<\/sup><\/p>\n\n\n\n

As a result, people with von Willebrand disease may have low levels of both VWF and FVIII, both of which need to be corrected in order to restore normal haemostasis.4<\/sup><\/p>\n\n\n\n\n\n

\n
\"\"<\/figure><\/div>\n\n\n\n\n\n

wilate\u00ae<\/sup><\/mark> contains VWF and FVIII in a balanced 1:1 ratio<\/a>*, which is similar to the activity ratio of VWF and FVIII in the plasma of healthy individuals.4<\/sup><\/em><\/strong><\/p>\n\n\n\n

*Based on von Willebrand factor and factor VIII activity levels.<\/p>\n<\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
<\/div>\n\n\n\n
\"\"<\/figure>\n\n\n\n\n\n

The balanced ratio of VWF and FVIII* may simplify dosing<\/a> and monitoring of wilate\u00ae<\/sup><\/mark>2<\/sup><\/em><\/strong><\/p>\n\n\n\n

*Based on von Willebrand factor and factor VIII activity levels.<\/p>\n\n\n\n

<\/div>\n<\/div><\/div>\n\n\n\n
<\/div>\n\n\n\n

Manufacturing of wilate\u00ae<\/sup><\/h2>\n\n\n\n

wilate\u00ae<\/sup><\/mark> is a high-purity, human VWF\/FVIII concentrate<\/strong><\/p>\n\n\n\n\n\n

\n
\"\"<\/figure>\n\n\n\n\n\n

wilate\u00ae<\/sup><\/mark> is made from pooled human plasma that has been collected in GMP-compliant donation centres, which are regularly inspected by Octapharma and national and international authorities9<\/sup><\/em><\/strong><\/p>\n\n\n\n

FVIII, factor VIII; GMP, good manufacturing practice; VWF, von Willebrand factor.<\/p>\n<\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\"\"<\/figure>\n\n\n\n\n\n

All individual plasma samples undergo extensive testing for viruses, including for HIV, hepatitis A, B and C and parvovirus B199, 10<\/sup><\/em><\/strong><\/p>\n\n\n\n

FVIII, factor VIII; HIV, human immunodeficiency virus; von Willebrand factor.<\/p>\n<\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n